NZYM B Novozymes A/S Class B

Trading by management and close relations of management

Trading by management and close relations of management

In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.

Investor Relations  
Tobias Bjorklund
Anders Enevoldsen
Disa Tuominen





Attachment



EN
31/05/2024

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. June 21, 2024Company announcement No. 23 1.Details of the person discharging managerial responsibilities/person closely associateda)NameNovo Holdings A/S2.Reason for the notificationa)Positi...

June 21, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement June 21, 2024 Company announcement No. 22 Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that Novo Nordisk Fonden has on its own behalf and on behalf of its wholly owned subsidiary Novo Holdings A/S notified Novonesis, that as of yesterday, Novo Nordisk Fonden and Novo Holdings A/S, indirectly and directly, respectively, holds a total of 53,743,600 A-shares (nominally DKK 107,487,200) and 65,672,555 B-shares (nominally DKK 131,345,110) corresponding to 25.50% of the entire issued share capital and 63.35% of the total vot...

June 21, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

The era of biosolutions. Outlook upgraded for 2024

The era of biosolutions. Outlook upgraded for 2024 Novonesis is performing very well and the 2024 outlook for pro forma organic sales growth is now expected at the upper end of the 5-7% range while the pro forma adjusted EBITDA margin is increased to 35-36%. Novonesis’ Capital Markets Day on June 18, 2024 will provide an introduction to Novonesis with insights on how the company intends to capture and accelerate organic sales growth. Also, Novonesis maintains the target for organic sales growth at 6-8% CAGR through 2025 with an adjusted EBITDA margin of ~37% and reconfirms the ambition to ...

June 17, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Incentive programs for the Executive Leadership Team, the Senior Leade...

Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees    June 6, 2024Company announcement No. 20  Incentive program for the Executive Leadership Team 2024-2026 In line with previous year, a new long-term incentive program (LTI) for the Executive Leadership Team covering the performance period 2024-2026 has been established. The program complies with the Remuneration Policy for the Executive Management and the Board of Directors of Novonesis, as approved at Novonesis Annual Shareholders’ Meeting on April 30, 2024. The L...

June 6, 2024 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B. Investor Relations  Tobias Bjorklund Anders Enevoldsen Disa Tuominen Attachment

May 31, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch